Raymond James Financial
HAE icon

Raymond James Financial’s Haemonetics HAE Stock Holding History

Raymond James Financial’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Sell
134,271
-3,707
-3% -$238K ﹤0.01% 2151
2026
Q1 		$7.78M Sell
137,978
-30,345
-18% -$1.98M ﹤0.01% 2221
2025
Q4 		$13.5M Sell
168,323
-155,970
-48% -$10.5M ﹤0.01% 1735
2025
Q3 		$15.8M Buy
324,293
+28,759
+10% +$1.78M 0.01% 1583
2025
Q2 		$22M Sell
295,534
-95,322
-24% -$6.31M 0.01% 1298
2025
Q1 		$24.8M Buy
390,856
+147,492
+61% +$10M 0.01% 1147
2024
Q4 		$19M Buy
+243,364
New +$19.5M 0.01% 1359

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's HAE Position: Q2 2026 in Review

Raymond James Financial reduced its Haemonetics (HAE) stake by 2.7% in Q2 2026, selling an estimated $238K and leaving 134,271 shares worth $10.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2151.

Raymond James Financial first reported a position in HAE in Q4 2024 and has held it in 7 quarters since. The position peaked at $24.8M in Q1 2025. 330 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Raymond James Financial held 134,271 shares of Haemonetics worth $10.1M as of Q2 2026.
  • Raymond James Financial sold 3,707 Haemonetics shares in Q2 2026, an estimated $238K.
  • Haemonetics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2151 holding.
  • Raymond James Financial first reported a position in Haemonetics in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Haemonetics position peaked at $24.8M in Q1 2025.
  • 330 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.